Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Eribulin in Recurrent or Metastatic TNBC
NCT06202313Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in triple-negative breast cancer (TNBC), sponsored by Shengjing Hospital of China Medical University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06202313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202313.